Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

TJ Biopharma Sells Rights to Lead Drug for $237m

publication date: Sep 27, 2024

Hangzhou’s TJ Biopharma sold the China rights for its CD73-targeted antibody to Sanofi in a deal worth up to $237 million. The antibody, uliledlimab, is designed to modulate the tumor microenvironment. Earlier this year, TJ became the heir to I-Mab’s China assets, including uliledlimab, when I-Mab moved its operations to the US. TJ will receive $36 million in an upfront payment and near-term milestone payments plus additional milestones that could bring the package to $237 million. More details....

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here